Jonathan Chong-yen Yeh, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Palliative Care | 6 | 2023 | 3478 | 0.800 |
Why?
|
| Visitors to Patients | 1 | 2021 | 35 | 0.780 |
Why?
|
| Cancer Care Facilities | 2 | 2021 | 401 | 0.780 |
Why?
|
| Organizational Policy | 1 | 2021 | 427 | 0.650 |
Why?
|
| Hospices | 1 | 2019 | 264 | 0.540 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2016 | 319 | 0.500 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2016 | 627 | 0.460 |
Why?
|
| Neoplasms | 7 | 2022 | 21596 | 0.440 |
Why?
|
| Terminal Care | 2 | 2022 | 1688 | 0.420 |
Why?
|
| Medical Oncology | 2 | 2022 | 2235 | 0.330 |
Why?
|
| Referral and Consultation | 2 | 2022 | 3527 | 0.300 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 2062 | 0.300 |
Why?
|
| Death | 2 | 2022 | 675 | 0.300 |
Why?
|
| Advance Care Planning | 1 | 2014 | 660 | 0.280 |
Why?
|
| Internship and Residency | 1 | 2023 | 5774 | 0.220 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 7901 | 0.180 |
Why?
|
| Antineoplastic Protocols | 1 | 2016 | 47 | 0.140 |
Why?
|
| Outpatients | 1 | 2021 | 1483 | 0.120 |
Why?
|
| Patient Dropouts | 1 | 2014 | 421 | 0.100 |
Why?
|
| Social Support | 1 | 2021 | 2117 | 0.100 |
Why?
|
| Education, Medical, Graduate | 1 | 2023 | 2283 | 0.100 |
Why?
|
| Superior Colliculi | 1 | 2011 | 99 | 0.090 |
Why?
|
| Inpatients | 1 | 2021 | 2495 | 0.090 |
Why?
|
| Curriculum | 1 | 2023 | 3589 | 0.090 |
Why?
|
| Disease Management | 1 | 2019 | 2450 | 0.080 |
Why?
|
| Receptors, Nicotinic | 1 | 2011 | 497 | 0.080 |
Why?
|
| Humans | 11 | 2023 | 742088 | 0.070 |
Why?
|
| Visual Pathways | 1 | 2011 | 565 | 0.070 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 3667 | 0.070 |
Why?
|
| Retinal Ganglion Cells | 1 | 2011 | 771 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 24913 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2019 | 4414 | 0.060 |
Why?
|
| Odds Ratio | 1 | 2016 | 9846 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2022 | 77098 | 0.060 |
Why?
|
| Axons | 1 | 2011 | 1681 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2019 | 4440 | 0.050 |
Why?
|
| Pediatrics | 1 | 2016 | 3462 | 0.050 |
Why?
|
| Translations | 1 | 2021 | 64 | 0.050 |
Why?
|
| Physician-Patient Relations | 1 | 2014 | 3215 | 0.050 |
Why?
|
| Retina | 1 | 2011 | 2611 | 0.040 |
Why?
|
| Hospitalization | 1 | 2019 | 10232 | 0.040 |
Why?
|
| Anxiety | 1 | 2014 | 4279 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 3915 | 0.040 |
Why?
|
| Policy | 1 | 2021 | 504 | 0.040 |
Why?
|
| Aged | 3 | 2019 | 162944 | 0.030 |
Why?
|
| Middle Aged | 3 | 2019 | 213127 | 0.030 |
Why?
|
| United States | 1 | 2021 | 69693 | 0.030 |
Why?
|
| Language | 1 | 2021 | 1458 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 11039 | 0.020 |
Why?
|
| Male | 3 | 2019 | 349538 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 62966 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 57683 | 0.020 |
Why?
|
| Female | 2 | 2019 | 379592 | 0.020 |
Why?
|
| Child | 1 | 2016 | 77478 | 0.020 |
Why?
|
| Adult | 3 | 2021 | 213712 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 3151 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2011 | 2723 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 5304 | 0.020 |
Why?
|
| Motivation | 1 | 2014 | 1968 | 0.010 |
Why?
|
| Pandemics | 1 | 2021 | 8328 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 7770 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2011 | 14554 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 21821 | 0.010 |
Why?
|
| Mice | 1 | 2011 | 81045 | 0.000 |
Why?
|
| Animals | 1 | 2011 | 168561 | 0.000 |
Why?
|